CureVac N.V. (CVAC)
- Previous Close
4.4400 - Open
4.4002 - Bid 4.4400 x 200
- Ask 4.4900 x 200
- Day's Range
4.3100 - 4.5100 - 52 Week Range
2.3700 - 5.0000 - Volume
437,057 - Avg. Volume
674,084 - Market Cap (intraday)
1.004B - Beta (5Y Monthly) 2.49
- PE Ratio (TTM)
4.90 - EPS (TTM)
0.9100 - Earnings Date Aug 13, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.30
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: CVAC
View More
Performance Overview: CVAC
Trailing total returns as of 6/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVAC
View MoreValuation Measures
Market Cap
1.01B
Enterprise Value
543.11M
Trailing P/E
4.90
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.69
Price/Book (mrq)
1.37
Enterprise Value/Revenue
0.91
Enterprise Value/EBITDA
2.09
Financial Highlights
Profitability and Income Statement
Profit Margin
34.50%
Return on Assets (ttm)
19.92%
Return on Equity (ttm)
33.04%
Revenue (ttm)
523.7M
Net Income Avi to Common (ttm)
180.66M
Diluted EPS (ttm)
0.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
438.33M
Total Debt/Equity (mrq)
5.78%
Levered Free Cash Flow (ttm)
92.39M
Research Analysis: CVAC
View MoreResearch Reports: CVAC
View MoreCureVac: Dropping Coverage
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
RatingPrice TargetCureVac Earnings: Early-Stage Pipeline Makes Progress; GSK Agreement and Reorganization Extend Cash
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
RatingPrice TargetCureVac: New Agreement With GSK Provides Capital Boost; Leaner Operations Should Extend Cash Runway
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
RatingPrice TargetCureVac Earnings: Reorganization Aims to Extend Cash Runway; Intellectual Property Battle Ongoing
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac’s first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
RatingPrice Target